Hospital and Tzu Chi University, Hualien, Taiwan
|
|
- Rudolf Greer
- 5 years ago
- Views:
Transcription
1 LUTS (2012) 4, ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou CHEN 1 and Hann-Chorng KUO 2 1 Department of Urology, Hualien Hospital, Hualien, Taiwan and 2 Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan Objectives: Intravesical injection of onabotulinumtoxina (i.e. Botox) provides effective treatment for overactive bladder. However, treatment-related adverse events (AEs) remain problems. This study investigated the effect of AEs after onabotulinumtoxina injection on the success rate for idiopathic detrusor overactivity (IDO). Methods: A total of 174 patients who received the first single intravesical onabotulinumtoxina 100U injection for refractory IDO were included. The onabotulinumtoxina related AEs including acute urinary retention (AUR), large postvoid residual (PVR, 150 ml), difficult urination, urinary tract infection, gross hematuria and general weakness were recorded. The success rate was determined based on patient perception of bladder condition improved by two scales. The short-term (3 months) and long-term (up to 24 months) success rates were analyzed according to the occurrence of these AEs. Results: A successful outcome was reported by 138 (79.3%) patients at 3 months. AUR occurred in 12 (6.9%) patients, large PVR developed in 81 (46.6%) and 73 (42%) needed straining to void. Gross hematuria occurred in 17 (9.8%) patients, urinary tract infection developed in 27 (15.5%) and general weakness was noted in 6 (3.4%). The occurrence of AUR did not affect the therapeutic results. Patients having large PVR and difficult urination had a significantly higher success rate at 3 months. Long-term success rates up to 24 months showed no significant difference between patients with and without AEs. Conclusions: AEs after intravesical 100U onabotulinumtoxina for IDO were frequently encountered. However, the occurrence of AUR, large PVR or difficult urination did not affect the final therapeutic outcome. Key words adverse events, detrusor overactivity, onabotulinumtoxina, overactive bladder 1. INTRODUCTION Intravesical injection of onabotulinumtoxina has recently been accepted as an alternative treatment for patients with overactive bladder (OAB) or detrusor overactivity (DO) refractory to antimuscarinic therapy. 1,2 OnabotulinumtoxinA injection provides an alternative for non-surgical augmentation of the dysfunctional bladder. About 50 80% of OAB patients with or without DO regained urinary continence or improved in urinary control. 3 5 Studies which decreased the dose of onabotulinumtoxina from 300 to 100U in the treatment of OAB found similar therapeutic effects. 5 8 Recent studies revealed a dose of 100U of onabotulinumtoxina has acceptable therapeutic effects and adverse events (AEs). 8,9 The reported AEs associated with intravesical onabotulinumtoxina injection are acute urinary retention (AUR), large postvoid residual (PVR), difficult urination and urinary tract infection (UTI). These AEs occurred in about 20 43% of patients in previous studies. 1,2,8 12 UTI is usually associated with the presence of large PVR. 9,12 In a previous study by the author, UTI occurred in 35% of patients, large PVR requiring clean intermittent catheterization (CIC) in about 30% of patients, and difficult urination occurred in 75% of patients after intravesical onabotulinumtoxina injection for OAB. 4 Although there is substantial evidence of the therapeutic efficacy of onabotulinumtoxina on motor and sensory dysfunction in OAB and DO, the incidence of treatment-related AEs remains high and this has limited the wider application of this novel treatment for patients with urinary incontinence The response duration of onabotulinumtoxina injection in patients with DO is closely related to the dose. Detrusor injection of 200U onabotulinumtoxina yielded a response duration of months, 11 whereas the Correspondence: Hann-Chorng Kuo, MD, Department of Urology, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung Yang Road, Hualien 970, Taiwan. Tel: ext. 2117; Fax: hck@tzuchi.com.tw Received 5 May 2011; revised 14 June 2011; accepted 7 August DOI: /j x
2 30 Yih-Chou Chen and Hann-Chorng Kuo therapeutic duration of 100U onabotulinumtoxina was 6 9 months. 13,14 However, the incidence of AEs is also closely related to the dose of onabotulinumtoxina. A randomized trial of different doses of onabotulinumtoxina in patients with DO found the incidence of large PVR was 30, 52 and 72% for the dose of onabotulinumtoxina from 100, 150 and 200U, respectively. 8 Doses greater than 150U of onabotulinumtoxina contributed minor additional, or clinically, relevant improvements in symptoms. Dose dependent changes in PVR were observed and the use of CIC was also dose dependent. 9 A recent study further revealed that onabotulinumtoxina can also reduce the expression of TRPV1 and P2X in the bladder wall, which correlates well with the reduction of urgency in OAB patients. 15 A primary peripheral effect of botulinum toxin A (BoNT-A) in the inhibition of release of, adenosine triphosphate, substance P, and reduction in the axonal expression of the capsaicin and purinergic receptors has been proposed. 16 These mechanisms of action also provide a rapid reduction of urgency in the first week after onabotulinumtoxina injection. 17 In addition to antinociceptive effect, the main mechanism of action of onabotulinumtoxina on IDO is inhibition of the release of acetylcholine that causes paralysis of affected detrusor. 18,19 It is difficult for onabotulinumtoxina to effect on sensory nerves without affecting motor function of the bladder. In order to achieve the reduction of urgency and DO it is rational to develop difficult urination and increased PVR after treatment. Therefore, the onabotulinumtoxina related AEs seem unavoidable and might be essential in the effective treatment. This study analyzed the AEs after intravesical onabotulinumtoxina 100U injection and the effect of these AEs on therapeutic outcome. The results may provide evidence for us to revisit the AEs of onabotulinumtoxina treatment and enable urologists to handle them when intravesical onabotulinumtoxina injection is planning to be used in treatment of patients with idiopathic DO (IDO). 2. METHODS A total of 174 patients who had received clinical trials of intravesical onabotulinumtoxina 100U injection for refractory DO and urinary incontinence were included in this study from 2005 to ,8,13,20 The inclusion criteria were urodynamic DO with or without urinary incontinence refractory to previous antimuscarinics for more than 3 months and free of UTI, stress urinary incontinence, bladder outlet obstruction or neurogenic bladder at enrollment. All patients received 100U of onabotulinumtoxina at different methods of intravesical injections including detrusor or suburothelial injection in the bladder body and/or bladder base including trigone injections. 8,13,20 All studies were approved by the institutional review board and ethics committee. All patients were informed about the advantage and possible AEs and written informed consent was obtained from all patients before onabotulinumtoxina injection. One hundred units of onabotulinumtoxina (BOTOX, Allergan, Inc., Irvine, CA, USA) was reconstituted to ml by normal saline for detrusor and suburothelial injections and to 10 ml with normal saline for bladder base injections. Detrusor injection was performed by injecting onabotulinumtoxina solution to sites about 1 mm in depth in the lateral, posterior wall and thedomeofthebladder,usingausinga23gaugeneedle in a rigid cystoscopic injection instrument (22 Fr, Richard-Wolf, Knittlingen, Germany). The injection sites were equally distributed in the bladder body. Suburothelial injection was performed using a procedure identical to that for detrusor injection except that the needle was inserted just into the suburothelial space and a ballooning formation was noted during injection. Bladder base injection was performed by injecting onabotulinumtoxina solution into 10 sites in the suburothelial space: two injections in the first row near the bladder neck, three injections in the second row anterior and five injections posterior to the interureteric ridge, about 0.5 cm away from the ureteral orifices. All procedures were performed transurethrally under intravenous general anesthesia in the operation room. Anticoagulant was discontinued 1 week before onabotulinumtoxina treatment. The bladder volume was kept at ml and the blood vessels were avoided during injections. An indwelling 14 Fr Foley catheter was placed overnight and the patients were discharged the next morning. Broad spectrum prophylactic antibiotics were given for 3 days. Videourodynamic study was routinely used for the diagnosis of DO and identifying the presence of bladder outlet obstruction or intrinsic sphincter deficiency. Patients with a baseline PVR of more than 150 ml were excluded from the clinical trials. The cystometric bladder capacity, voiding detrusor pressure, maximum flow rate (Q max ), and PVR were recorded. DO was classified as spontaneous or terminal DO depending on whether the uninhibited detrusor contractions occurred at the filling phase or on reaching bladder capacity, respectively. Repeat videourodynamic study was performed at baseline and every 3 months after intravesical BoNT-A injection. During the follow-up period, patients were requested to make follow-up visits regularly until their voiding condition returned to baseline. Uroflowmetry for Q max, voided volume and PVR were performed at each visit. The functional bladder capacity was calculated as the sum of voided volume and PVR. The voiding efficiency (VE) was calculated as the percentage of voided volume of functional bladder capacity. All patients were closely monitored at 1 2 weeks, 1 month, 3 months and every month thereafter until the response to BoNT-A had disappeared. All participants were followed up regularly according to our protocol until the therapeutic effect had disappeared. Patients who failed the treatment were not followed up after 6 months. The occurrence of urgency episodes and urgency incontinence were verified using a 3-day voiding diary. All patients were requested to grade the treatment outcome at 3 months after BoNT-A injection (primary end-point)
3 Adverse Effects of Botox on IDO 31 based on the patient perception of bladder condition (PPBC; scored from 0 to 6) of therapeutic effects and bothersome of AEs. 21 The treatment outcome was assessed using the PPBC. An improvement of PPBC scale by 2 was considered as having a successful outcome. Otherwise, the treatment was considered to have failed. The period between the treatment date and the visit that patients reported disappearance of the therapeutic effect was defined as the therapeutic duration. Any AE considered as possibly related to the BoNT-A treatment was recorded. These AEs included AUR, hematuria and general weakness in the early post-treatment period, and large PVR, straining to void, and UTI during the follow-up period. The success rate at 3 months was analyzed between patients with and without each AE. Kaplan-Meier survival curve was used to analyze the cumulative success rates with time between subgroups with and without each AEs. A P-value <0.05 was considered statistically significant. 3. RESULTS A total of 174 patients were studied including 85 women and 89 men aged from 18 to 94 with a median age of 67 years. Among the 79 male patients aged more than 50 years, 41 had undergone transurethral resection of the prostate and 38 had not. Bladder body injection was given to 129 patients and bladder base/trigonal injection was given to 45. There was no significant difference in the mean age of each demographic subgroup. The demographic distribution of patients and the success rates of each subgroup are listed in Table 1. At 3 months, a successful result was reported by 138 (79.3%) patients and failed treatment by 36 (20.7%) patients. The success rate at 3 months was not significantly different between any of the demographic or urodynamic variable subgroups. During the follow-up period, AUR occurred in 12 (6.9%) patients, large PVR 150 ml developed in 81 (46.6%) patients and 73 (42%) patients needed straining to void. Gross hematuria occurred in 17 (9.8%) patients, UTI developed in 27 (15.5%) patients and general weakness was noted in 6 (3.4%) patients (Table 2). Although AEs were bothersome problems after BoNT-A injection, the occurrence of AUR was not associated with a higher treatment failure rate. On the contrary, patients with large PVR or straining to void after treatment had higher success rate than those without these AEs. However, the development of UTI or hematuria was correlated with a lower success rate at 3 months. Figure 1 shows the changes of bladder capacity, Q max, PVR, voiding detrusor pressure and VE from baseline to 12 months after onabotulinumtoxina injection in subgroups with success or failure outcome assessed at 3 months. PVR and bladder capacity increased to a maximum and VE decreased to a minimum at 1 month, then slowly returned to baseline levels within 12 months. Figure 2 shows the cumulative success rate between AE subgroups. There was no significant difference in the TABLE 1. Comparison of the success rates at 3 months among idiopathic detrusor overactivity subgroups with different demographic and urodynamic variables Inn Success rate P-value Gender Female (80%) Male (79%) Age years (80%) <75 years (79%) Comorbidity Yes (77%) No (81%) Injection site Body (80%) Bladder base and trigone (78%) CBC <250 ml (76%) 250 ml (82%) Q max <10 ml/sec (83%) 10 ml/sec (77%) PVR <100 ml (78%) 100 ml (83%) VE <70% (82%) 70% (79%) DO 0.51 Spontaneous (85%) Terminal (72%) Male Pdet <30 cmh 2 O (76%) 30 cmh 2 O (81%) Female Pdet <20 cmh 2 O (80%) 20 cmh 2 O (80%) The treatment outcome was assessed using the patient perception of bladder condition (PPBC), an improvement of PPBC scale from baseline by 2 was considered as having a successful outcome. CBC, cystometric bladder capacity; DO, detrusor overactivity; Pdet, detrusor pressure; PVR, postvoid residual; Q max, maximum flow rate; VE, voiding efficiency. TABLE 2. Comparison of the success rates at 3 months between patient subgroups with and without adverse events Adverse event (n) Success (n = 138) Failure (n = 36) P-value AUR (12) 9 (75%) 3 (25%) No AUR (162) 129 (79.6%) 33 (20.4%) Large PVR 150 ml (81) 71 (87.7%) 10 (12.3%) Small PVR <150 ml (93) 67 (72%) 26 (28%) Straining to void (73) 67 (91.8%) 6 (8.2%) No straining to void (101) 71 (70.3%) 30 (29.7%) Hematuria (17) 10 (58.8%) 7 (41.2%) No hematuria (157) 128 (81.5%) 29 (18.5%) UTI (27) 17 (63%) 10 (37%) No UTI (147) 121 (82.3%) 26 (17.7%) Weakness (6) 3 (50%) 3 (50%) No weakness (168) 135 (83.3%) 33 (16.7%) AUR, acute urinary retention; PVR, postvoid residual; UTI, urinary tract infection. cumulative success rate between patients with and without AUR (P = 0.95), large PVR (P = 0.43), straining to void (P = 0.19) or UTI (P = 0.48). However, patients with gross hematuria (P = 0.01) and general weakness
4 32 Yih-Chou Chen and Hann-Chorng Kuo Fig. 1 Changes in postvoid residual (PVR), cystometric bladder capacity (capacity), detrusor pressure (Pdet), maximum flow rate (Q max ) and voiding efficiency with time after BoNT-A injection in subgroups with success or failure outcome assessed at 3 months. Data are expressed as mean ± standard error. Fig. 2 The Kaplan-Meier survival curves for the cumulative success rates of different patient subgroups with and without adverse events of acute urinary retention (AUR), large postvoid residual (PVR), difficult urination and urinary tract infection (UTI). The treatment outcome was assessed using the PPBC, an improvement of PPBC scale from baseline by 2 was considered as having a successful outcome.
5 Adverse Effects of Botox on IDO 33 (P = 0.05) had a lower long-term success rate compared with those without these AEs. 4. DISCUSSION This study found that the occurrence of AEs was high after 100U onabotulinumtoxina injection for patients with IDO. More than 40% of patients developed large PVR and needed straining to void, and 6.9% of patients had AUR during the first 3 months after treatment. However, the occurrence of these onabotulinumtoxina related AEs did not affect the likelihood of successful outcome. In the recent decade, intravesical onabotulinumtoxina injection has been shown to be an effective therapeutic alternative for IDO refractory to antimuscarinics. Urinary frequency and episodes of incontinence improved after onabotulinumtoxina injection. 22 Although clinical trials have provided evidence for the efficacy of onabotulinumtoxina in patients with OAB, the incidence of AEs remains high and also seems to have been underreported. Increased dose of onabotulinumtoxina increases the incidence of AE, especially large PVR and AUR needing CIC. 9 There is no agreement on the optimal dose, depth and the sites of onabotulinumtoxina injection in treating IDO. 1,4,8,11,13 In previous studies, the dose of BOTOX for IDO ranged from 300 to 100U, the percentage of patients with large PVR ranged from 0 to 72%. 1 5,11 13 and the percentage of patients needing CIC ranged from 1to43%. 1 5,9 12,23,24 Brubaker et al. used 200U BOTOX injection into the detrusor of women with refractory IDO. They found that approximately 60% of women had a clinical response but 43% developed increased PVR, of whom 75% developed UTI. 12 Dose-dependent AEs were further confirmed in a recently published study. Based on this multicentric placebo control trial, a dose of 100U was recommended as optimal for treating refractory OAB. 9 The incidence of AEs in this study is compatible with previous reports. This study found that the patients with an occurrence of large PVR and straining to void after intravesical 100U onabotulinumtoxina injection had significantly higher success rates at 3 months and no significant at long-term compared with those without these AEs. Our previous study and other reports also showed a decrease of voiding pressure at 1 month but returned thereafter. 8,10 Although voiding pressure returned 1 month after onabotulinumtoxina injection, the VE remained lower than the baseline, indicating the detrusor contractility cannot return in the early period of treatment. However, patients usually could accept the AEs of difficult urination and increased PVR in exchange of the reduction of urgency or urgency urinary incontinence. This result suggests lower detrusor contractility is necessary for the therapeutic effect of onabotulinumtoxina injection. In patients with neurogenic DO, detrusor underactivity is the treatment goal to achieve so that patients can regain continence and CIC is necessary after treatment The major concern is the dose effect of onabotulinumtoxina on detrusor contractility in patients with OAB. If the dose of onabotulinumtoxina is too high the detrusor contractility might be impaired too long and affect the satisfaction perceived by the patients. The mechanism of action of onabotulinumtoxina on OAB might be different from that on neurogenic detrusor overactivity. Reduction of sensory afferent activity might be more important that decrease of detrusor contractility in achieving a successful result in OAB. Although previous studies of decrease of sensory receptors in IDO is based on the trial using 200U onabotulinumtoxina, 15,16 our recent study also revealed a 100U dose is enough for the reduction of urgency and achieve satisfactory longterm effect. 8,13 Dmochowski et al. also demonstrated that dose of onabotulinumtoxina over 150U did not have additional benefits on clinical efficacy but might increase incidence of large PVR and the need for CIC. 9 If 100U of onabotulinumtoxina is adequate for decrease of these sensory receptors, it will not be necessary to use a higher dose so that AEs might be prevented. Although AEs are unavoidable in onabotulinumtoxina treatment for IDO, there are several risk factors that can be used for patient selection. Male gender, baseline PVR >100 ml and presence of comorbidity are independent risk factors for a higher incidence of AUR or large PVR after treatment. 28 Therefore, patients at risk of AEs should be fully counseled on the possibility of urinary retention and trained in CIC before the procedure. 29 After the first month, the AE of difficult urination will resolve and patients may feel improvement in urinary incontinence and urgency symptoms. 4,11 In this study, patients with UTI and gross hematuria had a less favorable success rate at 3 months after onabotulinumtoxina injection. The correlation of UTI and gross hematuria with a lower success rate could be due to increased bladder inflammation and exacerbated storage symptoms associated with UTI. Although over half of patients with UTI also had a successful result, the success rate was far less than in those without UTI. In conclusion, AUR, large PVR and straining to void are AEs after 100U onabotulinumtoxina injection for IDO. The occurrence of large PVR and straining to void did not affect the success rate at 3 months or long-term follow up. Patients with UTI after treatment had a lower success rate, but the long-term success rate was not affected. Disclosure All authors have no financial interest or relationship with any company included in the manuscript. REFERENCES 1. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63: Kessler TM, Danuser H, Schumacher M, Studer VE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24: Werner M, Schmid DM, Schussler B. Efficacy of botulinum- A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005; 192:
6 34 Yih-Chou Chen and Hann-Chorng Kuo 4. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin in patients with non-neurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66: Schulte-Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66: Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005; 96: Schmid DM, Sauermann P, Werner M et al. Experience with 100 cases treated with botulinum-a toxin injections in the detrusor muscle for idiopathic overactive. JUrol2006; 176: Kuo HC. Will suburothelial injection of a small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006; 68: Dmochowski R, Chapple C, Nitti VW et al. Efficacy and safety of onabotulinumtoxina for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. JUrol2010; 184: Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta PA. Comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum- A toxin. JUrol2005; 174: Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin- A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. JUrol2007; 177: Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. JUrol 2008; 180: Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. JUrol2007; 178: Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007; 100: Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. JUrol2005; 174: Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 2008; 54: Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26: Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8(Suppl 5): Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxina for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2011; 30: Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a singleitem global measure for patients with overactive bladder. Eur Urol 2006; 49: Anger JT, Weinberg A, Suttorp MJ, Litwin MS, Shekelle PG. Outcome of intravesical botulinum toxin for idiopathic overactive bladder syndrome: a systemic review of the literature. JUrol2010; 183: Khan S, Kessler TM, Apostolidis A et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. JUrol 2009; 181: Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. JUrol2009; 181: Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection. Urology 2008; 72: Schurch B, de Seze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. JUrol 2005; 174: Reitz A, Stohrer M, Kramer G et al. European experience of 200 cases treated with botulinum-a toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010; 58: Apostolidis A, Dasgupta P, Denys P et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55:
Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome
EUROPEAN UROLOGY 58 (2010) 919 926 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationHasheminejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, Iran
ORIGINAL ARTICLE Vol. 43 (6): 1122-1128, November - December, 2017 doi: 10.1590/S1677-5538.IBJU.2016.0622 Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity:
More informationProspective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder
Original Article Prospective randomized trial of vs botox in the treatment of idiopathic overactive bladder Waleed AlTaweel, Alaa Mokhtar, Danny M. Rabah 1 King Faisal Specialist Hospital and Research
More informationREVIEW ARTICLE. Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder
76 REVIEW ARTICLE Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder Marius Alexandru Moga, 1 Simona Banciu, 2 Oana Dimienescu, 3 Nicusor-Florin Bigiu, 4 Ioan Scarneciu 5 Abstract
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationVoiding Dysfunction. Yao-Chi Chuang,* Jonathan H. Kaufmann, David D. Chancellor, Michael B. Chancellor and Hann-Chorng Kuo,k
Voiding Dysfunction Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial Yao-Chi Chuang,* Jonathan
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1729 1735 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 891 896 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationOnabotulinumtoxinA for the treatment of overactive bladder
OnabotulinumtoxinA for the treatment of overactive bladder Clin. Invest. (2014) 4(3), 281 286 OnabotulinumtoxinA has recently been granted a license for use in overactive bladder (OAB). This review assesses
More informationOutcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder Michael K. Flynn,* Cindy L. Amundsen, MaryAnn Perevich, Fan Liu and George D. Webster
More informationO (P =.005) in the NDO group and from ± 9.92 cmh 2. O to ± cmh 2
MISCELLANEOUS Success Rate and Patients' Satisfaction Following Intradetrusor Dysport Injection in Patients with Detrusor Overactivity: A Comparative Study of Idiopathic and Neurogenic Types of Detrusor
More informationA Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder
A Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder Maria Paola Pascali, Giovanni Mosiello,* Armando Marciano, Maria Luisa Capitanucci, Antonio Maria Zaccara and Mario
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationBOTULINUM TOXIN IN LOWER URINARY TRACT
BOTULINUM TOXIN IN LOWER URINARY TRACT Selcuk Yucel, MD Professor in Urology and Pediatric Urology Acibadem University School of Medicine Department of Uroloy and Pediatric Urology Acibadem University
More informationBotulinum toxin-a for the treatment of overactive bladder: UK contributions
473096URO6210.1177/2051415812473096Journal of Clinical UrologySeth et al. 2013 Original Article Botulinum toxin-a for the treatment of overactive bladder: UK contributions Journal of Clinical Urology 6(2)
More informationIndividualizing medical treatment of overactive bladder
Review Article Tzu Chi Medical Journal 2018; 30(4): 195 199 Individualizing medical treatment of overactive bladder Hann Chorng Kuo a,b* a Department of Urology, Buddhist Tzu Chi General Hospital, Hualien,
More informationTherapeutic effects of transurethral incision of the bladder neck on primary bladder neck dysfunction refractory to alpha-adrenergic blockade in men
Formosan Journal of Surgery (2012) 45, 78e82 Available online at www.sciencedirect.com journal homepage: www.e-fjs.com ORIGINAL ARTICLE Therapeutic effects of transurethral incision of the bladder neck
More informationUse of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity
Use of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity Editorial Raluca Borcăiaș 1,2, A. Manu-Marin 3, S. Nedelea 1,2, S. Rascu 1,2, V. Jinga 1,2 1 Prof. Dr. Th. Burghele
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationABSTRACT ORIGINAL RESEARCH
Adv Ther (2013) 30:819 833 DOI 10.1007/s25-013-0054-z ORIGINAL RESEARCH OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant
More informationGOVINDARAJ N. RAJKUMAR, DOUGLAS R. SMALL, ABDUL W. MUSTAFA and GRAEME CONN Department of Urology, Southern General Hospital, Glasgow, UK
Original Article BTXA IN DETRUSOR FOR REFRACTORY IDIOPATHIC DOA RAJKUMAR et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationBotulinum Toxin Injection: A Review of Injection Principles and Protocols
Review Article Botulinum Toxin Injection International Braz J Urol Vol. 33 (2): 132-141, March - April, 2007 Botulinum Toxin Injection: A Review of Injection Principles and Protocols David E. Rapp, Alvaro
More informationINTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE
PEDIATRIC UROLOGY INTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE ABDOL-MOHAMMAD KAJBAFZADEH, SHAHRAM MOOSAVI,
More informationBotulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October :00-17:00
Botulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October 2012 14:00-17:00 Start End Topic Speakers 14:00 14:15 Introduction Mohammad
More informationBotulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction
European Urology European Urology 48 (2005) 984 990 Botulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction Heinrich Schulte-Baukloh
More informationeuropean urology 53 (2008)
european urology 53 (2008) 275 287 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology Botulinum Toxin A (Botox W ) Intradetrusor Injections in Adults with
More informationAcademic Editors: Joseph Jankovic and Flaminia Pavone Received: 17 January 2016; Accepted: 7 March 2016; Published: 16 March 2016
toxins Article Adverse Events of Intravesical Onabotulinum Toxin A Injection between Patients with Overactive Bladder and Interstitial Cystitis Different Mechanisms of Action of Botox on Bladder Dysfunction?
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationEMR template and postprocedure notes
EMR template and postprocedure notes Sample autopopulated text to create a BOTOX injection procedure report Information gathered from market research. These considerations are for reference only and should
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationMultiple Sclerosis. Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
Queen Square Uro-neurology course, London, UK 20 th -21 st October 2016 Multiple Sclerosis Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
More informationWhat is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
More informationManagement of Lower Urinary Tract Dysfunction After Radical Hysterectomy With or Without Radiotherapy for Uterine Cervical Cancer
ORIGINAL ARTICLE Management of Lower Urinary Tract Dysfunction After Radical Hysterectomy With or Without Radiotherapy for Uterine Cervical Cancer Fei-Chi Chuang, 1 Hann-Chorng Kuo 2 * Background/Purpose:
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationORIGINAL PAPER. Introduction. K.-D. Sievert, 1 C. Chapple, 2 S. Herschorn, 3 M. Joshi, 4 J. Zhou, 5 C. Nardo, 4 V. W. Nitti 6
ORIGINAL PAPER OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used
More informationTreatment of Lower Urinary Tract Symptoms and Overactive Bladder Focus on Bladder Sensory Innervation
REVIEW ARTICLE Treatment of LUTS and OAB Treatment of Lower Urinary Tract Symptoms and Overactive Bladder Focus on Bladder Sensory Innervation Ding-Yuan Chen, Hann-Chorng Kuo Department of Urology, Buddhist
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Text update pril 2014) J. Pannek (co-chair), B. Blok (co-chair), D. Castro-Diaz, G. del Popolo, J. Groen, G. Karsenty, T.M. Kessler, G. Kramer, M. Stöhrer Eur Urol 2009 Jul;56(1):81-8
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationUse of botulinum toxin for voiding dysfunction
Review Article Use of botulinum toxin for voiding dysfunction David Eldred-Evans, Prokar Dasgupta Department of Urology, Medical Research Council (MRC) Centre for Transplantation, King s College London,
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationURODYNAMICS IN MALE LUTS: NECESSARY OR WASTE OF TIME?
URODYNAMICS IN MALE LUTS: NECESSARY OR WASTE OF TIME? Andrea Tubaro, MD, FEBU Chairman Department of Urology Sant Andrea Hospital Sapienza University of Rome, Italy Disclosures Consultant, paid speaker,
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationTzu Chi Medical Journal
Tzu Chi Medical Journal 25 (2013) 98e102 Contents lists available at SciVerse ScienceDirect Tzu Chi Medical Journal journal homepage: www.tzuchimedjnl.com Original Article First-line antimuscarinic monotherapy
More informationKathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA
Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More informationEfficacy of Botulinum Toxin A Intradetrusor Injections for Non-neurogenic Urinary Urge Incontinence: A Randomized Double-Blind Controlled Trial
GYNAECOLOGY Efficacy of Botulinum Toxin A Intradetrusor Injections for Non-neurogenic Urinary Urge Incontinence: A Randomized Double-Blind Controlled Trial Corrine Jabs, MD, 1 Erica Carleton, MSc 2 1 Gynecology,
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Limited text update March 2015) B. Blok (Co-chair), J. Pannek (Co-chair), D. Castro Diaz, G. del Popolo, J. Groen, T. Gross (Guidelines ssociate), R. Hamid, G. Karsenty, T.M.
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationINJ. Original Article INTRODUCTION. Int Neurourol J 2010;14: doi: /inj pissn eissn
Original Article Int Neurourol J 21;14:267-271 pissn 293-4777 eissn 293-6931 International Neurourology Journal The Influence of Preoperative Bladder Outlet Obstruction on Continence and Satisfaction in
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationCASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1
1 CASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1 35 years old man, who previously has been completely healthy, was shot twice in the neck
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationExperience with Different Botulinum Toxins for the Treatment of Refractory Neurogenic Detrusor Overactivity
Neurourology Botulinum Toxins for Refractory Detrusor Overactivity International Braz J Urol Vol. 36 (1): 66-74, January - February, 2010 doi: 10.1590/S1677-55382010000100011 Experience with Different
More informationA systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages
/, 2017, Vol. 8, (No. 52), pp: 90338-90350 A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages Hui-Yun Gu 1,*,
More informationEfficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study
American Journal of Obstetrics and Gynecology (2005) 192, 1735 40 www.ajog.org Efficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study Matthias
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationEFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA
J Rehabil Med 2016; 48: 683 687 ORIGINAL REPORT EFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA Maping Huang, PhD 1,
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationIntravesical Drug Delivery for Dysfunctional Bladder
Intravesical Drug Delivery for Dysfunctional Bladder Yao-Chi Chuang Professor and Chief, Division of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan 成長於台南 建興國中 台南一中 2 Yao-Chi Chuang In connection
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationBotulinum Toxin a promising new treatment for overactive bladder
Botulinum Toxin a promising new treatment for overactive bladder C. Persu 1, D. Castro-Diaz 2, S.C. Gutui 3, J. Lavelle 3, P. Geavlete 1 1 Spitalul Clinic Sf Ioan, Bucuresti 2 University Hospital of Canary
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationThe Successful and Novel Treatment of Non-Neurogenic Detrusor- External Sphincter Dyssynergia (DESD) with Botulinum Toxin A
original article The Successful and Novel Treatment of Non-Neurogenic - External Sphincter Dyssynergia (DESD) with Botulinum Toxin A Tricia LC Kuo, MBBS, MRCSEd, M Med (Surg), FAMS, Lay Guat Ng, MBBS,
More informationUrodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우
Urodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우 Introduction Radical prostatectomy - treatment of choice for patients with localized prostate cancer. Urinary incontinence and/or
More informationUrodynamics Mismatch - Should We Listen to the Study, or the Patient?
Urodynamics Mismatch - Should We Listen to the Study, or the Patient? A Practical Approach to the Diagnosis and Treatment of Lower Urinary Tract Dysfunction Victor W. Nitti MD Professor of Urology and
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationThe new International Continence Society
ROLE OF CYSTOMETRY IN EVALUATING PATIENTS WITH OVERACTIVE BLADDER ADAM J. FLISSER AND JERRY G. BLAIVAS ABSTRACT Overactive bladder (OAB) can be caused by a variety of conditions. We believe that cystometrography
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2017) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler Guidelines Associates:
More informationAdditional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
Original Article - Female Urology Investig Clin Urol Posted online 217.6.27 Posted online 217.6.27 pissn 2466-493 eissn 2466-54X Additional low-dose antimuscarinics can improve overactive bladder symptoms
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2016) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler. Guidelines Associates:
More informationOnabotulinumtoxin - A Injections for the Treatment of Neurogenic Detrusor Overactivity
Onabotulinumtoxin - A Injections for the Treatment of Neurogenic Detrusor Overactivity Raluca Borcăiaș 1, S. Rașcu 1,2, V. Jinga 1,2, D. Mischianu 1,3, A. Manu-Marin 4 1 Carol Davila University of Medicine
More informationPractical urodynamics What PA s need to know. Gary E. Lemack, MD Professor of Urology and Neurology
Practical urodynamics What PA s need to know Gary E. Lemack, MD Professor of Urology and Neurology Urodynamics essential elements Urethral catheter Fill rate Catheter size Intravesical pressure measurements
More informationImpact of urethral catheterization on uroflow during pressure-flow study
Research Report Impact of urethral catheterization on uroflow during pressure-flow study Journal of International Medical Research 2016, Vol. 44(5) 1034 1039! The Author(s) 2016 Reprints and permissions:
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationDysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach)
Dysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach) Andrew Combs, PA-C Director, Pediatric Urodynamics Division of Pediatric Urology New York Presbyterian-Weill Cornell
More informationNEUROMODULATION FOR UROGYNAECOLOGISTS
NEUROMODULATION FOR UROGYNAECOLOGISTS Introduction The pelvic floor is highly complex structure made up of skeletal and striated muscle, support and suspensory ligaments, fascial coverings and an intricate
More informationeuropean urology 53 (2008)
european urology 53 (2008) 1245 1253 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Histological Changes in the Urothelium and Suburothelium of Human Overactive
More informationUrinary Adverse Events after Radiation Therapy for Prostate Cancer
Urinary Adverse Events after Radiation Therapy for Prostate Cancer Sexual Medicine Society of North America Scottsdale, Arizona 2016 Jaspreet S. Sandhu, MD Department of Surgery/Urology Memorial Sloan
More informationSupplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI Authors: Tatyana A. Shamliyan, MD, MS Senior Director, Evidence-Based Medicine Quality Assurance Elsevier 1600 JFK Blvd,
More informationManagement of Voiding Dysfunction after Prostate Radiotherapy
Management of Voiding Dysfunction after Prostate Radiotherapy Up to Date Symposium on Uro-Oncology December 7, 2012 Belo Horizonte, Brazil Jaspreet S. Sandhu, MD Department of Surgery/Urology Memorial
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More information